EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
shall have appeared in any printed publication or patent of a third party or shall have become a part of the public knowledge except as a result of a breach of this Agreement by Executive; or (iii) shall have been received by Executive from a third party having no obligation to the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New Jersey
This Employment Agreement (this “Agreement”), dated as of May 6, 2018 (the “Execution Date”), is entered into by and between TEVA PHARMACEUTICALS USA, INC., a Delaware corporation (“Teva USA”), and BRENDAN O’GRADY (the “Executive”).
AWARD AGREEMENTAward Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
AWARD AGREEMENTAward Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • Delaware
This SEPARATION AND GENERAL RELEASE AGREEMENT (this “Agreement”) is made as of October 1, 2019 (the “Effective Date”), between Teva Pharmaceuticals USA, Inc., a Delaware corporation (the “Company”), and Carlo de Notaristefani (the “Executive”). The Company and the Executive are collectively referred to herein as the “Parties.” Capitalized terms not otherwise defined herein shall have the meaning set forth in that Amended and Restated Employment Agreement dated as of February 7, 2018, between the Company and the Executive (the “Employment Agreement”).
Amendment to Employment AgreementEmployment Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Amendment to the Employment Agreement (the “Amendment”) is entered into on this 5 day of February 2020 (the “Effective Date”), and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel, Company No. 52-001395-4 (the “Company”, “Teva”), and Eli Kalif (“Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2020 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Employment Agreement (this “Agreement”), dated as of February 21, 2019 (the “Execution Date”), is entered into by and between TEVA PHARMACEUTICALS EUROPE B.V., a company incorporated under the laws of The Netherlands, Dutch Companies Register number 30110625 (“TPE” or “Company”), and GIANFRANCO NAZZI, born on 30 June 1968, nationality _____, passport number ________ (the “Executive”).
